<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709185</url>
  </required_header>
  <id_info>
    <org_study_id>1mgDST AVS</org_study_id>
    <nct_id>NCT04709185</nct_id>
  </id_info>
  <brief_title>AVS After 1mg DST to Determine Subtype in PA</brief_title>
  <official_title>Adrenal Venous Sampling Under 1 mg Overnight Dexamethasone Suppression Test to Determine Subtype in Primary Aldosteronism，a Single Center, Randomized, Double Blended, Placebo Controlled Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of different procedures of AVS(after 1mg DST or not) in determining the&#xD;
      subtypes and long-term outcomes of PA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All paticipants will be randomly divided into 1mg DST group(Intervention group,n=43) and&#xD;
      placebo group(Control group,n=43) and to determining the subtypes and to compare the&#xD;
      long-term outcomes of patients with PA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete biochemical remission</measure>
    <time_frame>1year</time_frame>
    <description>Compare the rate of complete biochemical remission between two groups. Blood was drawn to measure aldosterone, renin and potassium.According to PASO criteria, outcomes of adrenalectomy for unilateral primary aldosteronism were classified into complete, partial, and absent success, for both clinical and biochemical outcomes.The proportion of complete biochemical remission according to PASO consensus criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete clinical remission</measure>
    <time_frame>1 year</time_frame>
    <description>Compare the rate of complete clinical remission between two groups. Blood was drawn to measure aldosterone, renin and potassium.According to PASO criteria, outcomes of adrenalectomy for unilateral primary aldosteronism were classified into complete, partial, and absent success, for both clinical and biochemical outcomes.The proportion of complete biochemical remission according to PASO consensus criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily defined doses of antihypertensive agents</measure>
    <time_frame>1 year</time_frame>
    <description>The daily defined doses of antihypertensive agents of patients' blood pressure well controlled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Successful catheterization rate</measure>
    <time_frame>procedure</time_frame>
    <description>Calculate the successful rate of catheterization. Successful catheterization was defined as SI≥2 without ACTH stimulation or SI≥3 with ACTH stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 month</time_frame>
    <description>Including adrenal venous hemorrhage and related adrenal insufficiency, hypertensive urgencies, anaphylactic shock, venous thrombosis, pulmonary embolism.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>AVS after 1mg DST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients divided into AVS after 1mg DST group need to oral 1mg dexamethasone the night before AVS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVS after placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients divided into AVS after placebo group need to oral placebo the night before AVS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 1 MG Oral Tablet</intervention_name>
    <description>oral 1 mg dexamethasone at 23:00-24:00 the night before AVS</description>
    <arm_group_label>AVS after 1mg DST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo at 23:00-24:00 the night before AVS</description>
    <arm_group_label>AVS after placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or above, male or female, with legal capacity;&#xD;
&#xD;
          2. Patients who diagnosed as primary aldosteronism and willing to surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Patients with a history of malignant tumors or complicated with severe heart disease,&#xD;
             eGFR&lt;30ml/min/1.73m2, severe anemia (Hb&lt;60g/L), stroke or acute coronary syndrome&#xD;
             within 3 months, severe liver disease&#xD;
&#xD;
          3. Having contraindications or refusal to undergo AVS or unilateral adrenalectomy, or&#xD;
             allergy to ACTH;&#xD;
&#xD;
          4. PA combined with Cushing syndrome (including subclinical Cushing); or considering&#xD;
             glucocorticoid-suppressible aldosteronism (GRA) or adrenocortical carcinoma;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaomu Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaomu Li, PhD</last_name>
    <phone>86-21-64041990</phone>
    <email>li.xiaomu@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaomu Li, PhD</last_name>
      <phone>86-21-64041990</phone>
      <email>li.xiaomu@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary aldosteronism</keyword>
  <keyword>adrenal venous sampling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

